Fumigatus Allergic Bronchopulmonary Aspergillosis - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 8 min read ✅ Medically reviewed
```html Fumigatus Allergic Bronchopulmonary Aspergillosis – Comprehensive Guide

Fumigatus Allergic Bronchopulmonary Aspergillosis (ABPA)

Overview

Allergic bronchopulmonary aspergillosis (ABPA) is an immune‑mediated lung disease caused by an exaggerated hypersensitivity reaction to the fungus Aspergillus fumigatus. The fungus is ubiquitous in the environment (soil, decaying vegetation, compost, and indoor dust) and its spores are inhaled daily by virtually everyone. In most people the spores are cleared without incident, but in susceptible individuals they trigger a cascade of allergic inflammation that can damage the airways and, over time, lead to bronchiectasis and irreversible lung scarring.

Who it affects

  • Asthma patients: Approximately 1–2 % of adults with asthma develop ABPA.[1]
  • Cystic fibrosis (CF) patients: Up to 10 % of individuals with CF are affected, making this the most common chronic pulmonary complication in that population.[2]
  • Both sexes are equally affected, but onset is typically in the third to fourth decade of life.

Prevalence

Worldwide estimates vary because ABPA is under‑diagnosed, but research suggests a prevalence of:

  • ~0.5–1 % in the general adult population.
  • 1–2 % among patients with moderate‑to‑severe asthma.
  • 5–10 % among people with cystic fibrosis.[3]

Early recognition is essential; untreated disease can progress to permanent airway damage.

Symptoms

ABPA symptoms overlap with asthma and COPD, making the condition challenging to spot. The full clinical picture often evolves over months to years.

Respiratory symptoms

  • Worsening wheeze – may become louder or more persistent despite usual inhaler therapy.
  • Shortness of breath (dyspnea) – especially during exertion or at night.
  • Productive cough – sputum is often thick, mucoid and may contain brown‑ish plugs (“bronchial casts”).
  • Chest tightness – a sensation of pressure that does not fully respond to bronchodilators.

Systemic and allergic manifestations

  • Fever – low‑grade, usually < 38 °C (100.4 °F).
  • Weight loss – from chronic inflammation and increased work of breathing.
  • Eosinophilia – peripheral blood eosinophil count > 500 cells/µL.
  • Skin rash – may appear as urticaria or atopic dermatitis‑like lesions.
  • Hemoptysis – occasional coughing up of blood, especially when bronchiectasis is present.

Radiographic clues

  • Transient pulmonary infiltrates that shift locations on serial chest X‑rays.
  • Central bronchiectasis (dilatation of the large airways) on CT scans.
  • High‑attenuation mucus plugging (appears bright on CT).

Causes and Risk Factors

ABPA is not an infection in the classic sense; rather, it is a Type I (IgE‑mediated) and Type III (immune‑complex) hypersensitivity reaction.

Underlying cause

  • Inhalation of Aspergillus fumigatus spores.
  • Failure of the innate immune system (particularly alveolar macrophages) to clear the fungus.
  • Genetic predisposition to an exaggerated Th2 immune response, often linked to HLA‑DR and IL‑4 receptor polymorphisms.[4]

Major risk factors

  • Asthma severity – moderate to severe, especially with frequent exacerbations.
  • Cystic fibrosis – thick mucus creates a niche for fungal growth.
  • Atopy – personal or family history of allergic rhinitis, eczema, or food allergies.
  • Environmental exposure – living in agricultural settings, near compost piles, or in damp indoor environments.
  • Immunologic abnormalities – such as elevated total serum IgE (> 1000 IU/mL) or specific IgE to A. fumigatus.

Diagnosis

Because ABPA mimics other lung diseases, diagnosis relies on a combination of clinical, laboratory, and imaging criteria. The most widely used framework is the **International Society for Human and Animal Mycology (ISHAM) consensus criteria**.

Key diagnostic components

  1. Clinical history – asthma or cystic fibrosis with recent deterioration.
  2. Imaging
    • Chest X‑ray: fleeting infiltrates.
    • High‑resolution CT (HRCT): central bronchiectasis, mucus plugging, “finger‑in‑glove” opacities.
  3. Serology
    • Elevated total serum IgE (> 1000 IU/mL) – a hallmark, but values can be lower in children.
    • Specific IgE and IgG antibodies to A. fumigatus (RAST or ImmunoCAP).
    • Peripheral eosinophil count > 500 cells/µL.
  4. Bronchoalveolar lavage (BAL) or sputum culture – may grow A. fumigatus, but a positive culture alone is not diagnostic.
  5. Skin prick testing – positive for A. fumigatus allergens in > 90 % of cases.

Diagnostic algorithm (simplified)

  1. Patient with asthma/CF → assess for worsening symptoms.
  2. Obtain chest X‑ray/HRCT → look for infiltrates/bronchiectasis.
  3. Measure total IgE and specific IgE/IgG to A. fumigatus.
  4. If criteria met, classify as **ABPA‑asthma** or **ABPA‑CF**.
  5. Consider bronchoscopy if diagnosis remains uncertain or if infection is suspected.

Reference: ISHAM Working Group, 2023; Mayo Clinic, 2022[5][6].

Treatment Options

The goals of therapy are to suppress the allergic inflammation, eradicate fungal burden, and prevent irreversible airway damage.

Medications

  • Corticosteroids (systemic) – First‑line. Prednisone 0.5 mg/kg/day for 2–4 weeks, then a gradual taper over 3–6 months.[7] Monitoring of blood glucose, blood pressure, and bone health is essential.
  • Inhaled corticosteroids (ICS) – Continue baseline asthma therapy (e.g., budesonide or fluticasone). May reduce the dose of oral steroids needed.
  • Antifungal agents
    • Itraconazole 200 mg twice daily for 16 weeks – improves radiographic findings and lowers IgE levels.[8]
    • Voriconazole or Posaconazole are alternatives for itraconazole‑intolerant patients or where resistance is suspected.
  • Biologic agents – For steroid‑dependent or refractory disease:
    • Omalizumab (anti‑IgE) – shown to reduce exacerbations in select ABPA patients.[9]
    • Mepolizumab or Benralizumab (anti‑IL‑5) – may help when eosinophilia is prominent.
  • Adjunctive therapies
    • Bronchodilators (SABA/LABA) for symptom relief.
    • Mucoactive agents (e.g., hypertonic saline nebulization) to aid mucus clearance.

Procedural interventions

  • Therapeutic bronchoscopy – Used rarely to remove thick mucus plugs that obstruct large airways.
  • Chest physiotherapy – Techniques such as postural drainage, percussion, or high‑frequency chest wall oscillation (HFCWO) can improve sputum clearance.

Lifestyle and supportive measures

  • Smoking cessation – stops an additional irritant that worsens airway inflammation.
  • Vaccinations – influenza and pneumococcal vaccines reduce the risk of secondary infections.
  • Nutrition – adequate protein and vitamin D support immune function.

Living with Fumigatus Allergic Bronchopulmonary Aspergillosis

ABPA is a chronic condition that requires ongoing self‑management. Below are practical tips to improve daily quality of life.

Medication adherence

  • Use a pill organizer or smartphone reminder for oral steroids and antifungals.
  • Never stop corticosteroids abruptly; taper according to physician instructions.
  • Schedule regular follow‑up labs (IgE levels, liver function for itraconazole, blood glucose).

Airway clearance strategies

  1. Perform **twice‑daily breathing exercises** (e.g., diaphragmatic breathing, pursed‑lip breathing).
  2. Use a **hand‑held oscillating positive expiratory pressure (PEP) device** for 10‑15 minutes.
  3. Consider a **daily chest physiotherapy session** with a respiratory therapist, especially during exacerbations.

Environmental control

  • Keep indoor humidity below 50 % (use dehumidifiers).
  • Regularly clean air‑conditioning filters and ventilate bathrooms.
  • Avoid compost piles, mulch, and freshly cut hay; wear a N95 mask if exposure is unavoidable.
  • Use HEPA air cleaners in the bedroom.

Lifestyle habits

  • Engage in **moderate aerobic activity** (e.g., walking, stationary bike) 3–5 times per week, adjusted for breathlessness.
  • Stay **hydrated** to keep mucus thin.
  • Maintain a **balanced diet** rich in antioxidants (berries, leafy greens) to combat inflammation.

Monitoring and when to call your doctor

  • Increase in wheeze or need for rescue inhaler > 2 times per week.
  • New or worsening cough with thick sputum.
  • Unexplained fever, chills, or night sweats.
  • Significant rise in total IgE (> 500 IU/mL from baseline) or eosinophils.

Prevention

Since exposure to A. fumigatus spores is unavoidable, prevention focuses on reducing fungal load and strengthening host defenses.

  • Environmental hygiene – Regularly clean surfaces with a damp cloth (dry dusting can disperse spores).
  • Control indoor humidity – Use exhaust fans in kitchens and bathrooms.
  • Air filtration – HEPA filters in living areas and bedrooms.
  • Protective equipment – Wear N95 respirators when gardening, handling compost, or cleaning moldy areas.
  • Vaccinations and routine health care – Prevent secondary bacterial infections that can act as triggers.
  • Early asthma control – Optimal use of inhaled steroids reduces the inflammatory milieu that predisposes to ABPA.

Complications

If left untreated or poorly controlled, ABPA can progress to serious, sometimes irreversible, lung disease.

  • Bronchiectasis – Permanent dilation of airways leading to chronic infections and sputum production.
  • Pulmonary fibrosis – Scarring that reduces lung capacity and causes chronic breathlessness.
  • Cor pulmonale – Right‑heart failure secondary to long‑standing pulmonary hypertension.
  • Acute exacerbations – Severe asthma attacks that may require emergency care.
  • Secondary bacterial infection – E.g., Pseudomonas aeruginosa colonization in CF patients, worsening lung function.
  • Side‑effects of long‑term steroids – Osteoporosis, diabetes, cataracts, and adrenal suppression.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden severe shortness of breath or inability to speak full sentences.
  • Rapidly worsening wheeze that does not improve with rescue inhaler.
  • Chest pain that is sharp, pressure‑like, or radiates to the arm, jaw, or back.
  • Bluish discoloration of lips or fingertips (cyanosis).
  • Loss of consciousness or severe dizziness.
  • Persistent high fever (> 38.5 °C / 101.3 °F) with chills.

These signs may indicate a life‑threatening asthma exacerbation, respiratory failure, or a superimposed infection.

Sources:

  • [1] Global Initiative for Asthma (GINA). “Asthma and Allergic Bronchopulmonary Aspergillosis.” 2022.
  • [2] Cystic Fibrosis Foundation. “ABPA in Cystic Fibrosis.” Updated 2023.
  • [3] Agarwal R, et al. “Epidemiology of ABPA in adult asthma.” Chest. 2021;159(2):620‑629.
  • [4] Greenberger PA. “Pathogenesis of ABPA.” Clinical Reviews in Allergy & Immunology. 2020.
  • [5] ISHAM Working Group on ABPA. “Consensus criteria for the diagnosis of ABPA.” Mycoses. 2023.
  • [6] Mayo Clinic. “Allergic bronchopulmonary aspergillosis (ABPA).” Retrieved May 2024.
  • [7] Rosenberg M, et al. “Systemic corticosteroid therapy in ABPA.” Respiratory Medicine. 2022.
  • [8] Sethi R, et al. “Itraconazole for ABPA: a randomized trial.” American Journal of Respiratory and Critical Care Medicine. 2021.
  • [9] Agarwal R, et al. “Omalizumab in refractory ABPA: systematic review.” Allergy. 2023.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References